A role for combination therapy in pulmonary arterial hypertension. Results of an expert workshop;Kombinationstherapie der pulmonal-arteriellen hypertonie (PAH). Ergebnisse eines experten-workshops

Pneumologie

Volumn 59, Issue 10, 2005, Pages 730-735

  Behr, Jürgen ^a   Borst, M M ^b   Winkler, J ^c   Hoeper, M ^d   Halank, M ^e   Ghofrani, A ^f   Klose, H ^g   Wilkens, H ^h   Stahler G ⁱ  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b CARITAS KRANKENHAUS   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f UNIVERSITY HOSPITAL GIESSEN   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h SAARLAND UNIVERSITY   (Germany)

ⁱ Klinik Lowenstein   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BERAPROST; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; SILDENAFIL;

AEROSOL; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDICATION; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ANTIHYPERTENSIVE AGENTS; CONTROLLED CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; PIPERAZINES; SULFONAMIDES;

EID: 27644544637     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-915556     Document Type: Conference Paper

References (17)

1. Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788
2. Mc Laughlin W, Shillington A, Rich S. Survival in Primary Pulmonary Hypertension; the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482
3. Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347 (5): 322-329
4. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346 (16): 896-903
5. Wilkens H, Guth A, Konig J et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104 (11): 1218-1222
6. Ghofrani HA, Wiedemann R, Rose F et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136 (7): 515-522
7. Ghofrani HA, Rose F, Schermuly RT et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42 (1): 158-164
8. Hoeper MM, Faulenbach C, Golpon H et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24 (6): 1007-1010
9. Humbert M, Barst RJ, Robbins IM et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24 (3): 353-359
10. Petkov V, Ziesche R, Mosgoeller W et al. Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax 2001; 56 (9): 734-736
11. Hoeper MM, Taha N, Bekjarova A et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003; 22 (2): 330-334
12. Seyfarth HJ, Pankau H, Hammerschmidt S et al. Bosentan improves exercise tolerance and tei index in patients with pulmonary hypertension and prostanoid therapy. Chest 2005; in press
13. http://www.cotherix.com.
14. D'Alanzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 343-349
15. Wensel R, Opitz CF, Anker SD et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002; 106 (3): 319-324
16. Nagaya N, Nishikimi T, Uematsu M et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102 (8): 865-870
17. Raymond RJ, Hinderliter AL, Willis PW et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39 (7): 1214-1219